Green synthesis of MnO2-embedded Rauvolfia tetraphylla leaves (MnO2@RTL) for crystal violet dye removal and as an antibacterial agent.

The application of green synthesized nanocomposites for the prevention of environmental pollution is increasing nowadays. Here, a green composite has been synthesized by embedding MnO2 on Rauvolfia tetraphylla leaves using its leaf extract hereinafter termed as MnO2@RTL, and demonstrated for crystal violet (CV) dye removal from simulated and real wastewater. The surface properties of the material were determined by scanning electron microscopy-energy dispersive X-ray spectroscopy (SEM-EDX), Fourier transform infrared spectra (FTIR), X-ray diffraction (XRD), and Brunauer-Emmet-Teller (BET) surface area, pHZPC, and zeta potential. The material exhibits a remarkable adsorption capacity of 61.162 mg/g at 328 K and pH 7. The adsorption was best fitted with Pseudo-second-order kinetic (R2 = 0.998) and a combination of Langmuir and Freundlich isotherm model (R2 = 0.994-0.999). The thermodynamic study revealed spontaneous (ΔG values = - 2.988 to - 4.978 kJ/mol) and endothermic (ΔH values = 6.830 to 11.018 kJ/mol) adsorption. After adsorption, 80% regeneration occurred with 50% methanol, and recycled up to five times. Advantageously, the material was able to remove CV dye in the presence of coexistent ions and from industrial wastewater, confirming field applicability. The adsorption capacity of the material is superior to previously reported materials. The standard deviation and relative standard deviations have been evaluated to be 0.000422-0.000667 and 0.473-0.749%, which suggests the reliability of the experiments. The exhausted material, after recycling, was pyrolyzed to overcome the disposal problem. It was established as a secondary adsorbent with 73% efficiency which makes the material win-win. The material showed antibacterial properties with Staphylococcus aureus bacteria with a zone of inhibition 5 mm.

Role of Exosomes in Epithelial-Mesenchymal Transition.

Epithelial-mesenchymal transition (EMT) is a fundamental process driving cancer metastasis, transforming non-motile cells into a motile population that migrates to distant organs and forms secondary tumors. In recent years, cancer research has revealed a strong connection between exosomes and the EMT. Exosomes, a subpopulation of extracellular vesicles, facilitate cellular communication and dynamically regulate various aspects of cancer metastasis, including immune cell suppression, extracellular matrix remodeling, metastasis initiation, EMT initiation, and organ-specific metastasis. Tumor-derived exosomes (TEXs) and their molecular cargo, comprising proteins, lipids, nucleic acids, and carbohydrates, are essential components that promote EMT in cancer. TEXs miRNAs play a crucial role in reprogramming the tumor microenvironment, while TEX surface integrins contribute to organ-specific metastasis. Exosome-based cancer metastasis research offers a deeper understanding about cancer and an effective theranostic platform development. Additionally, various therapeutic sources of exosomes are paving the way for innovative cancer treatment development. In this Review, we spotlight the role of exosomes in EMT and their theranostic impact, aiming to inspire cancer researchers worldwide to explore this fascinating field in more innovative ways.

Clinical Theranostics Trademark of Exosome in Glioblastoma Metastasis.

Glioblastoma (GBM) is an aggressive type of cancer that has led to the death of a large population. The traditional approach fails to develop a solution for GBM's suffering life. Extensive research into tumor microenvironments (TME) indicates that TME extracellular vesicles (EVs) play a vital role in cancer development and progression. EVs are classified into microvacuoles, apoptotic bodies, and exosomes. Exosomes are the most highlighted domains in cancer research. GBM cell-derived exosomes participate in multiple cancer progression events such as immune suppression, angiogenesis, premetastatic niche formation (PMN), ECM (extracellular matrix), EMT (epithelial-to-mesenchymal transition), metastasis, cancer stem cell development and therapeutic and drug resistance. GBM exosomes also carry the signature of a glioblastoma-related status. The exosome-based GBM examination is part of the new generation of liquid biopsy. It also solved early diagnostic limitations in GBM. Traditional therapeutic approaches do not cross the blood-brain barrier (BBB). Exosomes are a game changer in GBM treatment and it is emerging as a potential platform for effective, efficient, and specific therapeutic development. In this review, we have explored the exosome-GBM interlink, the clinical impact of exosomes on GBM biomarkers, the therapeutics signature of exosomes in GBM, exosome-based research challenges, and future directions in GBM. Therefore, the GBM-derived exosomes offer unique therapeutic opportunities, which are currently under preclinical and clinical testing.